ASTRO’s first bladder cancer guideline recommends trimodal therapy as a curative option for selected patients and defines ...
PROFESSIONAL powerlifting comes with some serious risks. Bones and joints can be broken in pursuit of incredible personal ...
AstraZeneca has reported positive Phase III VOLGA results for perioperative Imfinzi (durvalumab) plus neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cance ...
AstraZeneca's Imfinzi combined with Pfizer's Padcev cut the risk of death in muscle-invasive bladder cancer patients by 42%, ...
Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.
Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary ...
VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...
The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.
Perioperative treatment with durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) compared with radical cystectomy ...
AstraZeneca's IMFINZI plus enfortumab vedotin reduced disease progression/recurrence risk by 49% and mortality by 42% in muscle-invasive bladder ...
Georgia Lee Hampshire, 27, was taking up to 14g of a drug every day at the height of her 10-year addiction, suffering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results